安徽丰原药业股份有限公司2025年第二次临时股东会决议公告

Core Points - The company held its second extraordinary general meeting of shareholders in 2025 on November 11, 2025, with no new proposals or changes to previous resolutions [1][2] - The meeting was conducted in compliance with relevant laws and regulations [8][27] Meeting Details - The meeting took place at the company's headquarters in Hefei, Anhui, starting at 14:30 [4][3] - A combination of on-site and online voting was utilized for the meeting [5] - The total number of shares represented at the meeting was 128,275,798, accounting for 27.5996% of the total voting shares [9] Resolutions Passed - The proposal to repurchase and cancel part of the restricted stock was approved, with 98.8459% of the votes in favor [11] - The amendment to the company's articles of association was approved with 98.8278% support [14] - The revision of the shareholders' meeting rules was passed with 98.7505% approval [17] - The amendment to the board meeting rules received 98.8231% approval [20] - The revision of the independent director working system was approved with 98.7512% support [23] Legal Opinions - The meeting was witnessed by lawyers from Anhui Jingqiao Law Firm, confirming that the meeting's procedures and resolutions were in accordance with the law [27] Additional Information - The company announced plans to repurchase and cancel 88,200 shares of restricted stock due to the departure of one employee and the failure of two others to meet performance criteria [29][30] - Following the repurchase, the company's registered capital will decrease by 88,200 yuan [30]